Related Experiment Video
Updated: May 12, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Ceftaroline - a cause for neutropenia
R H Rimawi1, A Frenkel, P P Cook
1Division of Infectious Diseases, East Carolina University - Brody School of Medicine, Greenville, NC 27834, USA. RamzyRimawi@hotmail.com
What Is Known And Objective:
The US Food and Drug Administration approved ceftaroline in 2010 for the treatment of community-acquired pneumonia and skin and soft-tissue infections. The most common adverse reactions are diarrhoea, nausea and rash. To present the first case of neutropenia directly related to ceftaroline.
Case Summary:
A 90-year-old female was given ceftaroline for treatment of a pneumonia complicated by methicillin-resistant Staphylococcus aureus bacteraemia and possible vertebral osteomyelitis. After 25 days of ceftaroline, she developed neutropenia. Ceftaroline was discontinued and her white blood cell count returned to normal within one week.
What Is New And Conclusion:
Although neutropenia is a potential cephalosporin class effect, we present the first case of neutropenia directly related to ceftaroline. Agranulocytosis and neutropenia are rare, yet potentially life-threatening adverse effects of cephalosporins. Healthcare providers should be aware of the potential for ceftaroline to cause neutropenia, particularly in patients treated for greater than two weeks.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Bacterial Protein Synthesis
Drugs that Destabilize Microtubules
Anthelminthic Agents
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Pyelonephritis II: Diagnostic Studies and Management